HHS would review brand-name drugs at least yearly and could label some prices “excessive,” including by comparing them to prices in five other countries. If a drug is deemed excessively priced, the bill would end certain exclusivity protections and require open licensing so other manufacturers can compete while paying royalties. It also adds public reporting, a database, and civil penalties for noncompliance.
Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
Prescription Drug Price Relief Act of 2025 is a House bill in committee. The latest recorded action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Latest action on H.R. 3546: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Who this affects: The bill most directly affects brand-name drug manufacturers whose products could be reviewed and labeled excessively priced, which can trigger loss of exclusivity protections and open licensing. It also affects generic and biosimilar manufacturers that could use those open, non-exclusive licenses to enter the market sooner, while paying royalties and meeting price-related conditions. Patients, insurers, and public programs could be affected if additional competition lowers prices for drugs that receive an excessive-price finding. HHS and FDA would take on specific review, licensing, enforcement, and accelerated application deadlines, and NIH would receive funding from certain civil penalties collected under the reporting rules.
Why this matters: This bill matters because it would create a federal system for identifying brand-name drugs with “excessive” prices and then using open licensing to bring in competitors sooner. That could change what patients, insurers, and public programs pay for certain medicines, especially when U.S. prices exceed prices in the listed reference countries. It also increases transparency by requiring detailed manufacturer reports and by publishing a public database and yearly summaries to Congress. The real-world effects on prices, access, and innovation are not guaranteed by the bill’s text and would depend on how the Secretary applies the standards and how manufacturers respond.
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
Keep acting on Modern Action
Compare the broader issue and related bills without leaving Modern Action.
Officially: Prescription Drug Price Relief Act of 2025
HHS would review brand-name drugs at least yearly and could label some prices “excessive,” including by comparing them to prices in five other countries. If a drug is deemed excessively priced, the bill would end certain exclusivity protections and require open licensing so other manufacturers can compete while paying royalties. It also adds public reporting, a database, and civil penalties for noncompliance.
Use this page to support, oppose, or ask Congress to amend H.R.3546. Modern Action explains what the bill does, helps identify the right senators or representative, and drafts a bill-specific message you can edit and send.
Where it stands
Sitting in Energy and Commerce
No vote scheduled. Constituent contact is what moves bills out of committee.
↓ Why your message matters here
This bill is sitting in committee with no scheduled vote — which means a small number of constituent messages can decide whether it moves forward or quietly dies.
Enter your ZIP to see how your senators and member of Congress have voted, sponsored, or spoken on this bill.
The debate
Where this bill is in the process
Introduced
Introduced in House
House Committee
Under House committee consideration
Latest: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (5/21/2025)
House Floor Vote
Voted on by House
Passed House
Approved by House
Senate Review
Sent to Senate for consideration
Passed Both Chambers
Approved by both House and Senate
Signed into Law
Signed by the President
For more detail
Choose one clear position: support, oppose, or amend. Then pick any reasons or personal context you want included. Modern Action uses that input and the bill context to draft a message you can edit and send.
Congressional offices prioritize messages from their own constituents. Modern Action uses your address to route the drafted message to your House representative when that is the most relevant target for this bill.
The draft includes the bill number, your position, the reasons you selected, any personal context you added, and a direct ask such as voting yes, voting no, cosponsoring, opposing, or seeking changes. You stay in control because you can edit the message before sending.
This page gives you an opportunity to support, oppose, or ask for changes to Prescription Drug Price Relief Act of 2025, then contact the elected officials who can act. Modern Action drafts the message from your position and the reasons you select.
Modern Action keeps the action tied to the bill itself: what it does, where it is in the process (committee), which office can still act, and what ask belongs in the message.
You are not starting from a blank form. Modern Action drafts the message around H.R.3546, your stance, and the reasons you choose, then lets you edit and send when ready.
